Vismodegib
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Basal Cell
Conditions
Carcinoma, Basal Cell
Trial Timeline
Sep 17, 2015 → Mar 31, 2019
NCT ID
NCT02674009About Vismodegib
Vismodegib is a pre-clinical stage product being developed by Roche for Carcinoma, Basal Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT02674009. Target conditions include Carcinoma, Basal Cell.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02674009 | Pre-clinical | Completed |
| NCT02371967 | Pre-clinical | Completed |
| NCT01944943 | Phase 2 | Terminated |
| NCT01367665 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Basal Cell